Completed PHASE3 INTERVENTIONAL NCT00269763

Clinical Use and Safety of the Fentanyl Transdermal Therapeutic System (TTS) in the Management of Pain in Patients With Cancer

The Clinical Use and Safety of TTS (Fentanyl) in the Management of Pain in Patients With Cancer

Sponsor: Alza Corporation, DE, USA

Interventions Fentanyl Transdermal Therapeutic System (TTS)

Updated 5 times since 2017 Last updated: May 18, 2011 Started: Oct 31, 1987 Completion: Apr 30, 1988

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Cancer and Pain and is currently completed. Alza Corporation, DE, USA leads this study, which shows 5 recorded versions since 1987 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 1987

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alza Corporation, DE, USA

Data source: Alza Corporation, DE, USA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.